- Home
- OSCR vs RYTM Comparison
OSCR vs RYTM Comparison
Compare OSCR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSCR
- RYTM
- Stock Information
- Founded
- OSCR 2012
- RYTM 2008
- Country
- OSCR United States
- RYTM United States
- Employees
- OSCR N/A
- RYTM N/A
- Industry
- OSCR Accident &Health Insurance
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- OSCR Finance
- RYTM Health Care
- Exchange
- OSCR Nasdaq
- RYTM Nasdaq
- Market Cap
- OSCR 3.7B
- RYTM 3.8B
- IPO Year
- OSCR 2021
- RYTM 2017
- Fundamental
- Price
- OSCR $12.03
- RYTM $61.74
- Analyst Decision
- OSCR Hold
- RYTM Strong Buy
- Analyst Count
- OSCR 7
- RYTM 12
- Target Price
- OSCR $20.21
- RYTM $74.92
- AVG Volume (30 Days)
- OSCR 4.0M
- RYTM 940.6K
- Earning Date
- OSCR 05-07-2025
- RYTM 05-06-2025
- Dividend Yield
- OSCR N/A
- RYTM N/A
- EPS Growth
- OSCR N/A
- RYTM N/A
- EPS
- OSCR 0.10
- RYTM N/A
- Revenue
- OSCR $9,177,564,000.00
- RYTM $130,126,000.00
- Revenue This Year
- OSCR $24.21
- RYTM $43.84
- Revenue Next Year
- OSCR $0.55
- RYTM $65.62
- P/E Ratio
- OSCR $120.30
- RYTM N/A
- Revenue Growth
- OSCR 56.54
- RYTM 68.06
- 52 Week Low
- OSCR $11.47
- RYTM $35.17
- 52 Week High
- OSCR $23.79
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- OSCR 38.79
- RYTM 61.94
- Support Level
- OSCR $12.16
- RYTM $59.54
- Resistance Level
- OSCR $12.67
- RYTM $62.83
- Average True Range (ATR)
- OSCR 0.91
- RYTM 4.27
- MACD
- OSCR -0.01
- RYTM 1.00
- Stochastic Oscillator
- OSCR 23.43
- RYTM 92.04
About OSCR Oscar Health Inc.
Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.